Perrigo win approval for generic Klaron; Oracle buys drug safety software company Relsys;

> Perrigo has won FDA approval for its generic version of Sanofi-Aventis' acne treatment Klaron. Report

> Software giant Oracle has acquired Relsys International, a provider of drug safety and risk management solutions with analytics for the health sciences industry. Report

> KV Pharmaceutical's plans to cut 1,700 jobs will lead to a handful of layoffs in Texas. KV announced its cuts in February. Report

> The British government plans to lean heavily on the world's biggest drug companies to get them to voluntarily relinquish patents on a broad array of drug technologies that could be used to spur new research into therapies to treat HIV and a host of neglected diseases. Report

> Pfizer said it has completed its offering of $13.5 billion in senior unsecured notes and plans to use some of the proceeds to finance its $68 billion buy of rival Wyeth. Report

> Sweden's Orexo says that a mid-stage trial of an experimental therapy for allergic rhinitis failed to demonstrate efficacy in reducing symptoms when compared to a placebo. But the developer still believes that the drug could work against COPD. Report

> A Chicago-based private equity firm is investing $200 million into a new company that will buy and develop late-stage therapeutics. GTCR Golder Rauner LLC has created Actient Pharmaceuticals and tapped a former Abbott Labs exec, Ed Fiorentino, to run the start-up. Actient will be charged with buying approved therapies as well as drugs that are nearing regulatory approval. Report

> Richard Hollis (photo), the controversial CEO and founder of drug developer Hollis-Eden, has been fired from his post for an unspecified offense. The San Diego Union-Tribune's Terri Somers reports that Hollis was terminated for cause, meaning he could have been fired for a list of potential infractions, including "misappropriation of funds, fraud, engaging in an activity that is harmful to the company or conviction of a crime." Report

> GlaxoSmithKline has struck an innovative research deal with a noted professor at University College London aimed at developing an antibody that can be combined with an existing drug to fight amyloidosis. The disease is characterized by the buildup of proteins in the body leading to organ failure. GSK report

> Pfizer has snapped Cephalon's VP and general manager of Oncology Elizabeth Barrett to become regional president for its U.S. Oncology unit. Report

And Finally... A consortium involving NHS Blood and Transplant, the Scottish National Blood Transfusion Service and the Wellcome Trust is backing a new research project that will attempt to create 'synthetic' blood from embryonic stem cells. Backers say that the new blood supply should be ready for testing in humans within three years. Report